Skip to main content

Advertisement

Table 3 Treatment status of nintedanib switched from pirfenidone

From: Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis

  (n = 30)
Administration period of nintedanib (months) 5.30 [2.84, 11.8]
Discontinued 18 (60.0%)
 Discontinued within 6 months 16 (53.3%)
 Reason for discontinuation
  Liver injury 3 (10.0%)
  Anorexia + weight loss 3 (10.0%)
  Deterioration of physical condition 3 (10.0%)
  Death 3 (10.0%)
  Acute exacerbation of IPF 3 (10.0%)
  Diarrhea 1 (3.3%)
  Nausea 1 (3.3%)
  Rash 1 (3.3%)
Continued 12 (40.0%)
 Continued without interruption/dose reduction 7 (23.3%)
 Need at least ≥1 interruption and/or dose reduction 5 (16.7%)
 Reason for interruption and/or dose reduction
  Liver injury 2 (6.7%)
  Diarrhea 2 (6.7%)
  Fever 1 (3.3%)
  1. Categorical data are presented as numbers (percentages)
  2. Abbreviation: IPF idiopathic pulmonary fibrosis